CardiolRx
Sponsors
Cardiol Therapeutics Inc.
Conditions
Acute MyocarditisRecurrent Pericarditis
Phase 2
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
CompletedNCT05180240
Start: 2022-07-28End: 2025-02-04Updated: 2026-06-17
Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
CompletedNCT05494788
Start: 2023-01-09End: 2024-09-06Updated: 2025-10-20
“Impact of CardiolRx on Myocardial Recovery in patients with Acute Myocarditis. A double-blind, placebo-controlled trial (ARCHER)”
CompletedCTIS2024-514639-10-00
Start: 2023-03-30End: 2024-11-25Target: 35Updated: 2025-01-28
Phase 3
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
RecruitingNCT06708299
Start: 2025-04-07End: 2026-10-21Target: 110Updated: 2026-09-10
IMpAct of CardiolRxTM oVer 6 months following IL-1 Blocker cessation in pERICarditis patients – MAVERIC: A randomized, double-blind, placebo-controlled trial
Not yet recruitingCTIS2024-517688-21-00
Target: 54Updated: 2025-11-28